Outset Medical Reports First-Quarter Results
Rhea-AI Summary
Outset Medical (Nasdaq: OM) reported Q1 2026 results: revenue of $27.9M (-6% YoY) and recurring revenue of $22.5M roughly flat year-over-year. Gross margin expanded to 43.4% with record product and service margins. Net loss narrowed to $19.0M; cash totaled $161M. The company reiterated 2026 revenue guidance of $125M–$130M and non-GAAP gross margin in the low‑to‑mid 40% range.
AI-generated analysis. Not financial advice.
Positive
- Gross margin expanded >600 basis points to 43.4%
- Record product gross margin of 52.4%
- Service and other gross margin improved to 25.5%
- Recurring revenue stable at $22.5M
- Quarter-end cash position of $161M
Negative
- Total revenue declined 6% year-over-year to $27.9M
- Product revenue decreased 13% to $18.6M
- Operating expenses increased 6% to $29.0M
- Net loss of $19.0M for Q1 2026
Key Figures
Market Reality Check
Peers on Argus
OM fell 5.45% while several peers like BSGM (+39.91%), QSI (+6.08%) and CATX (+4.66%) traded higher, with only VMD down (-8.24%). This points to a stock-specific reaction rather than a broad medical device move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Earnings call schedule | Neutral | -2.0% | Announcement of Q1 2026 earnings release date and conference call details. |
| Apr 08 | Inducement equity grant | Neutral | +2.9% | RSU inducement awards granted to new commercial leadership and employee hires. |
| Apr 06 | Executive appointment | Positive | +0.5% | Appointment of new EVP of Commercial to drive Tablo adoption across care settings. |
| Feb 11 | Q4 & 2025 earnings | Positive | -16.3% | Q4 and full-year 2025 growth, margin expansion, strong cash and 2026 guidance. |
| Jan 27 | FDA 510(k) clearance | Positive | +14.3% | FDA clearance for next-generation Tablo platform with cybersecurity enhancements. |
Recent history shows mostly aligned reactions to operational and strategic updates, with one notable divergence where positive earnings and guidance coincided with a sharp selloff.
Over the last few months, Outset Medical has progressed through several key milestones. An FDA 510(k) clearance for the next-generation Tablo platform on Jan 27, 2026 coincided with a 14.29% gain. Q4 and full-year 2025 results on Feb 11, 2026 showed revenue of $119.5M and expanding gross margins, yet the stock fell 16.3%. Governance and management updates in April, including a new EVP of Commercial and inducement grants, saw modestly positive or neutral moves. Today’s Q1 2026 report fits into this pattern of margin improvement and steady recurring revenue.
Market Pulse Summary
This announcement highlights a trade-off between revenue pressure and margin improvement. Q1 2026 net revenue declined 6% to $27.9M, while gross margin increased to 43.4% and product and service margins reached record levels. Net loss narrowed to $19.0M, and cash totaled $161M. The company reiterated $125M–$130M revenue guidance and low- to mid-40% non-GAAP gross margin for 2026. Investors may watch recurring revenue stability, operating expense discipline, and progress on the next-generation Tablo launch.
Key Terms
non-GAAP financial
GAAP financial
gross margin financial
basis points financial
stock-based compensation financial
litigation charges regulatory
AI-generated analysis. Not financial advice.
SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the first quarter ended March 31, 2026.
First Quarter and Recent Highlights
- Net revenue totaled
$27.9 million , a decrease of6% compared to$29.8 million in the first quarter of 2025. - Recurring revenue consisting of Tablo consumables and services was
$22.5 million , roughly even with the prior-year period. - Gross margin expanded by more than 600 basis points over the prior-year period to
43.4% (43.8% on a non-GAAP basis). Product gross margin of52.4% and service and other gross margin of26.7% were record highs. - Net cash used during the quarter of
$12 million was less than previously forecasted, resulting in a strong cash position, including restricted cash, cash equivalents and short-term investments, of$161 million at quarter-end.
“We delivered a solid first quarter and continued to make meaningful progress on our path to profitability, driven by disciplined execution and another quarter of record gross margin performance,” said Leslie Trigg, Chair and Chief Executive Officer. “With utilization strong and service margins expanding, we remain focused on driving broader adoption of Tablo across care settings and confident in our full-year outlook.”
First Quarter 2026 Financial Results
Revenue for the first quarter was
Gross profit of
Operating expenses of
Excluding stock-based compensation expense and litigation charges, non-GAAP operating expenses were
Net loss was
Total cash, including restricted cash, cash equivalents and short-term investments, was
2026 Financial Guidance
Outset reiterated its 2026 revenue guidance of
Webcast and Conference Call Details
Outset will host a conference call today, May 7, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its first quarter 2026 financial results. Those interested in joining the conference call may do so by dialing (646) 307-1963 or toll-free (800) 715-9871 and referencing conference ID 1632568. Participants are encouraged to register more than 15 minutes before the start of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
The Company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. As listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release, the Company’s GAAP financial measures include stock-based compensation expense and litigation charges incurred outside of the ordinary course of business in connection with the stockholder class action and relative derivative lawsuits as disclosed in the Company’s latest annual and quarterly reports. Stock-based compensation is a non-cash expense. In addition, litigation charges related to the above-described matters are excluded because they constitute non-routine litigation costs, arise outside of the ordinary course of the Company’s business, and are not indicative of its recurring operating results or underlying performance trends. As such, management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the Appendix A of this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues, gross margin, operating expenses, capital expenditures, cash use, cash burn, cash position, profitability and outlook; statements about the sufficiency of the Company’s cash balances through cashflow breakeven; statements regarding the anticipated impacts and benefits of the Company’s cost reduction actions, initiatives to optimize the commercial organization and improve forecasting and order visibility, and restructurings; statements regarding anticipated customer orders or other business opportunities including the expected size, closing and timing thereof; statements regarding the Company’s overall business strategy, plans and objectives of management; statements regarding the anticipated launch and timing of product enhancements and new features, as well as new or expanded services, and the expected benefits, performance, and impact thereof; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors (including changes in tariff or trade laws and policies) on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.
Investor Contact
Investors@outsetmedical.com
| Outset Medical, Inc. Condensed Statements of Operations (in thousands, except per share amounts) (unaudited) | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | |||||||||
| Revenue: | ||||||||||
| Product revenue | $ | 18,550 | $ | 21,294 | ||||||
| Service and other revenue | 9,313 | 8,458 | ||||||||
| Total revenue | 27,863 | 29,752 | ||||||||
| Cost of revenue: | ||||||||||
| Cost of product revenue(2) | 8,833 | 11,002 | ||||||||
| Cost of service and other revenue | 6,935 | 7,684 | ||||||||
| Total cost of revenue | 15,768 | 18,686 | ||||||||
| Gross profit(1) | 12,095 | 11,066 | ||||||||
| Gross margin(1) | 43.4 | % | 37.2 | % | ||||||
| Operating expenses: | ||||||||||
| Research and development(2) | 5,618 | 5,515 | ||||||||
| Sales and marketing(2) | 13,279 | 13,652 | ||||||||
| General and administrative(2)(3) | 10,117 | 8,298 | ||||||||
| Total operating expenses | 29,014 | 27,465 | ||||||||
| Loss from operations | (16,919 | ) | (16,399 | ) | ||||||
| Interest income and other income, net | 1,527 | 1,976 | ||||||||
| Interest expense | (3,369 | ) | (3,560 | ) | ||||||
| Loss on extinguishment of term loan | — | (7,685 | ) | |||||||
| Loss before provision for income taxes | (18,761 | ) | (25,668 | ) | ||||||
| Provision for income taxes | 217 | 115 | ||||||||
| Net loss | $ | (18,978 | ) | $ | (25,783 | ) | ||||
| Net loss per share, basic and diluted | $ | (1.03 | ) | $ | (3.66 | ) | ||||
| Shares used in computing net loss per share, basic and diluted | 18,373 | 7,038 | ||||||||
| (1) Gross profit and gross margin by source consisted of the following: | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | |||||||||
| Gross profit | ||||||||||
| Product revenue | $ | 9,717 | $ | 10,292 | ||||||
| Service and other revenue | 2,378 | 774 | ||||||||
| Total gross profit | $ | 12,095 | $ | 11,066 | ||||||
| Gross margin | ||||||||||
| Product revenue | 52.4 | % | 48.3 | % | ||||||
| Service and other revenue | 25.5 | % | 9.2 | % | ||||||
| Total gross margin | 43.4 | % | 37.2 | % | ||||||
| (2) Includes stock-based compensation expense as follows: | ||||||||||
| Three Months Ended | ||||||||||
| Stock-based compensation expense | March 31, | |||||||||
| 2026 | 2025 | |||||||||
| Cost of revenue | $ | 111 | $ | 117 | ||||||
| Research and development | 820 | 559 | ||||||||
| Sales and marketing | 458 | 479 | ||||||||
| General and administrative | 2,064 | 1,822 | ||||||||
| Total stock-based compensation expense | $ | 3,453 | $ | 2,977 | ||||||
| (3) Includes non-ordinary course litigation charges related to stockholder class action and related derivative lawsuits as follows: | ||||||||||
| Three Months Ended | ||||||||||
| Litigation charges | March 31, | |||||||||
| 2026 | 2025 | |||||||||
| General and administrative | $ | 112 | $ | — | ||||||
| Total litigation charges | $ | 112 | $ | — | ||||||
| Outset Medical, Inc. Condensed Balance Sheets (in thousands, except per share amounts) | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 30,562 | $ | 35,006 | ||||
| Short-term investments | 126,144 | 133,940 | ||||||
| Accounts receivable, net | 25,322 | 28,329 | ||||||
| Inventories | 49,650 | 47,609 | ||||||
| Prepaid expenses and other current assets | 5,031 | 5,999 | ||||||
| Total current assets | 236,709 | 250,883 | ||||||
| Restricted cash | 3,829 | 3,829 | ||||||
| Property and equipment, net | 4,073 | 4,670 | ||||||
| Operating lease right-of-use assets | 4,410 | 4,797 | ||||||
| Finance lease right-of-use assets | 80 | — | ||||||
| Other assets | 353 | 317 | ||||||
| Total assets | $ | 249,454 | $ | 264,496 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,440 | $ | 554 | ||||
| Accrued compensation and related benefits | 8,754 | 10,735 | ||||||
| Accrued expenses and other current liabilities | 11,599 | 9,433 | ||||||
| Accrued warranty liability | 1,352 | 1,374 | ||||||
| Deferred revenue, current | 12,641 | 13,795 | ||||||
| Operating lease liabilities, current | 1,795 | 1,739 | ||||||
| Finance lease liabilities, current | 26 | — | ||||||
| Total current liabilities | 37,607 | 37,630 | ||||||
| Deferred revenue | 366 | 406 | ||||||
| Operating lease liabilities | 2,797 | 3,271 | ||||||
| Finance lease liabilities | 59 | — | ||||||
| Term loan | 96,937 | 96,237 | ||||||
| Total liabilities | 137,766 | 137,544 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred Stock, | — | — | ||||||
| Common stock, | 18 | 18 | ||||||
| Additional paid-in capital | 1,302,097 | 1,298,138 | ||||||
| Accumulated other comprehensive income | (73 | ) | 172 | |||||
| Accumulated deficit | (1,190,354 | ) | (1,171,376 | ) | ||||
| Total stockholders' equity | 111,688 | 126,952 | ||||||
| Total liabilities and stockholders' equity | $ | 249,454 | $ | 264,496 | ||||
| Outset Medical, Inc. Condensed Statements of Cash Flows (in thousands) (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities | $ | (12,844 | ) | $ | (25,663 | ) | ||
| Net cash provided by (used in) investing activities | 7,899 | (78,079 | ) | |||||
| Net cash provided by financing activities | 501 | 55,656 | ||||||
| Net decrease in cash, cash equivalents and restricted cash | (4,444 | ) | (48,086 | ) | ||||
| Cash, cash equivalents and restricted cash at beginning of the period | 38,835 | 127,343 | ||||||
| Cash, cash equivalents and restricted cash at end of the period(1) | $ | 34,391 | $ | 79,257 | ||||
| (1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): | ||||||||
| March 31, | ||||||||
| 2026 | 2025 | |||||||
| Cash and cash equivalents | $ | 30,562 | $ | 75,928 | ||||
| Restricted cash | 3,829 | 3,329 | ||||||
| Total cash, cash equivalents and restricted cash* | $ | 34,391 | $ | 79,257 | ||||
| * The total cash, including restricted cash, cash equivalents and investment securities as of March 31, 2026 was | ||||||||
| Appendix A | ||||||||||
| Outset Medical, Inc. Results of Operations – Non-GAAP (in thousands, except per share amounts) (unaudited) | ||||||||||
| Reconciliation between GAAP and non-GAAP net loss per share: | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | |||||||||
| GAAP net loss per share, diluted | $ | (1.03 | ) | $ | (3.66 | ) | ||||
| Stock-based compensation expense | 0.19 | 0.42 | ||||||||
| Litigation charges | 0.01 | — | ||||||||
| Non-GAAP net loss per share, diluted | $ | (0.83 | ) | $ | (3.24 | ) | ||||
| Reconciliation between GAAP and non-GAAP net loss: | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | |||||||||
| GAAP net loss, diluted | $ | (18,978 | ) | $ | (25,783 | ) | ||||
| Stock-based compensation expense | 3,453 | 2,977 | ||||||||
| Litigation charges | 112 | — | ||||||||
| Non-GAAP net loss, diluted | $ | (15,413 | ) | $ | (22,806 | ) | ||||
| Reconciliation between GAAP and non-GAAP results of operations: | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | ||||||||||
| 2026 | 2025 | |||||||||
| GAAP gross profit | $ | 12,095 | $ | 11,066 | ||||||
| Stock-based compensation expense | 111 | 117 | ||||||||
| Non-GAAP gross profit | $ | 12,206 | $ | 11,183 | ||||||
| GAAP gross margin | 43.4 | % | 37.2 | % | ||||||
| Stock-based compensation expense | 0.4 | 0.4 | ||||||||
| Non-GAAP gross margin | 43.8 | % | 37.6 | % | ||||||
| GAAP research and development expense | $ | 5,618 | $ | 5,515 | ||||||
| Stock-based compensation expense | (820 | ) | (559 | ) | ||||||
| Non-GAAP research and development expense | $ | 4,798 | $ | 4,956 | ||||||
| GAAP sales and marketing expense | $ | 13,279 | $ | 13,652 | ||||||
| Stock-based compensation expense | (458 | ) | (479 | ) | ||||||
| Non-GAAP sales and marketing expense | $ | 12,821 | $ | 13,173 | ||||||
| GAAP general and administrative expense | $ | 10,117 | $ | 8,298 | ||||||
| Stock-based compensation expense | (2,064 | ) | (1,822 | ) | ||||||
| Litigation charges | (112 | ) | — | |||||||
| Non-GAAP general and administrative expense | $ | 7,941 | $ | 6,476 | ||||||
| GAAP total operating expense | $ | 29,014 | $ | 27,465 | ||||||
| Stock-based compensation expense | (3,342 | ) | (2,860 | ) | ||||||
| Litigation charges | (112 | ) | — | |||||||
| Non-GAAP total operating expense | $ | 25,560 | $ | 24,605 | ||||||
